Evaluation of effect Duloxtine in paclitaxel neuroathy

Evaluation of effect and safety of using duloxetine to prevention of paclitaxel induced Neuropathy in breast cancer patients of Imam_Reza Shiraz Clinic in 1403, a clinical trial study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241014063365N1

Enrollment

124

Registered

2025-02-24

Start date

2024-10-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Control group: Placebo drug duloxetine 30 mg twice a day for 3 months while injecting paclitaxel. Intervention 2: Intervention group: duloxetine 30 mg twice a day for 3 months while i

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Breast cancer under treatment with paclitaxel Non metastatic breast cancer

Exclusion criteria

Exclusion criteria: Diabet Pregnancy Chronic Heppatic,Renal and cardiac disease breastfeeding

Design outcomes

Primary

Measure	Time frame
Neuropathy. Timepoint: At the beginning of the study, 2, 3, and 6 months after starting to take duloxetine. Method of measurement: McGill pain questionare (MPQ)-DN? Questionnaire-Visual analogue scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahya Nouri

Shiraz University of Medical Sciences

Mahyanoori1400@gmail.com+98 71 3647 4332

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026